There is certainly an endless amount of risks that can go wrong with a small biotech like IPIX. 10Ks are ugly. You are correct that they spell out everything conceivable that can go wrong. And what is not going as planned like P. That is where a PR can help us understand what will in most like outcome. The 10K is through June, sounds like a lot is happening since. The Aspire agreement calls for funding on entering an agreement with another Co. Although it didn’t sound like Leo wanted to dilute anymore. Which is why he signed a Non Binding agreement. So things must be looking good. Outside of the P trial results, which no one knows, the B deal sounds very promising. If a Big Pharma wants UP too, they added it and did it to come to mutually beneficial terms IMO. Now there are risks of the BP backing out, but if you have promising compounds and your including UP, I think that would be very low. DD at this point is agreeing to the legal terms of the binding agreement.